4 / 24
Page 40
Notes:
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
Pharmacology Congress 2017
July 24-25, 2017
July 24-25, 2017 Melbourne, Australia
8
th
World Congress on
Pharmacology and Toxicology
Effects of selective PDE-2 inhibitor BAY60-7550, PDE-5 inhibitor Sildenafil and PDE-9 inhibitor PF-
04447943 on learning and memory in the passive avoidance test in naive mice
Guner Ulak, Emine Bektaş, Füruzan Yıldız Akar, Oguz Mutlu
and
Faruk Erden
Kocaeli University, Turkey
P
hosphodiesterases (PDE) are enzymes that hydrolyze cAMP and/or cGMP throughout the body, including the brain.
Preventing the breakdown of cAMP by PDE inhibitors promotes memory. PDE inhibitors present a novel therapeutic
approach with which to arrest cognitive decline or possibly reverse the decline with cognition enhancement. The aim of this
study was to investigate effects of BAY 60-7550 (a PDE2 inhibitor), Sildenafil (a PDE5 inhibitor) and PF-04447943 (a PDE9
inhibitor) on emotional memory in naive mice using Passive Avoidance (PA) test. Mice were trained in a one trial step-
through PA apparatus for evaluating emotional memory; whereas, decrease in retention latency indicate an impairment of
memory. BAY60-7550 (1 and 3 mg/kg), Sildenafil (3 and 10 mg/kg) or PF-04447943 (1 and 3 mg/kg), (n=12-15 per group) was
administered intra-peritoneally 30, 60 and 60 minutes, respectively before the acquisition session of PA test. One way Anova
post hoc Tukey’s test was used for the statistical analysis of the data. The results of this study revealed that there was significant
difference between the first day latency of the animals. Drug treatment, significantly prolonged the retention latency of PA
test in the second day compared to control group (3 mg/kg BAY 60-7550 vs. control p<0.05, 10 mg/kg Sildenafil vs. control
p<0.05, 3 mg/kg PF-04447943 vs. control p<0.01). Our results confirm that BAY 60-7550, Sildenafil and PF-04447943, enhance
emotional memory of mice in the PA test. Further studies and different cognition models are needed to support our results and
enlighten whether these effects are test dependent or not.
Biography
Guner Ulak has completed her PhD from Dicle University, School of Medicine and Postdoctoral studies from Kocaeli University, School of Medicine, Turkey.
She is the Director of Pharmacology Department, Kocaeli University, Turkey. She has published more than 70 papers in English, 45 in Turkish and has given
many poster presentations.
gunerulak@yahoo.comGuner Ulak et al., Clin Exp Pharmacol 2017, 7:4 (Suppl)
DOI: 10.4172/2161-1459-C1-020